Last updated: September 7, 2026
Esketamine hydrochloride is the active pharmaceutical ingredient in Johnson & Johnson’s Spravato nasal spray, the leading branded medicine in the rapid-acting antidepressant market. Spravato generated approximately $1 billion in global sales in 2024, up from about $689 million in 2023 and $518 million in 2022, according to Johnson & Johnson disclosures. Growth is being driven by broader diagnosis of treatment-resistant depression, improved payer coverage, expanded physician adoption, and increasing use beyond the initial induction period.[1]
The commercial outlook remains positive, but access restrictions, administration-site requirements, competing ketamine services, and eventual U.S. generic entry will constrain the trajectory. The product’s most important intellectual-property protection is associated with intranasal delivery and methods of treating depression, rather than the esketamine molecule itself.
What is esketamine hydrochloride and how is Spravato used?
Esketamine hydrochloride is the S-enantiomer of ketamine hydrochloride. It is an N-methyl-D-aspartate receptor antagonist administered as a nasal spray under the brand name Spravato.
The FDA approved Spravato in February 2019 for adults with treatment-resistant depression in combination with an oral antidepressant.[2] The agency later approved the product for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior, although evidence of reduced suicide risk itself was not established.[3]
Treatment is administered in a certified health-care setting. Patients are monitored for sedation, dissociation, blood-pressure increases and other adverse effects. The product is subject to a Risk Evaluation and Mitigation Strategy requiring certified prescribers and pharmacies, controlled dispensing, and post-dose observation.[4]
Primary commercial indications
| Indication |
FDA status |
Commercial relevance |
| Treatment-resistant depression in adults |
Approved in 2019 |
Core revenue base |
| Major depressive disorder with acute suicidal ideation or behavior |
Approved in 2020 |
Supports hospital and specialty-clinic use |
| Monotherapy for treatment-resistant depression |
Regulatory expansion reported in 2025 |
Could increase prescriber flexibility and patient reach |
| Bipolar depression |
Not an approved Spravato indication |
Off-label ketamine use remains a competitive factor |
| Chronic pain |
Not an approved Spravato indication |
Ketamine clinics compete outside the labeled market |
How large is the esketamine hydrochloride market?
The commercial market is concentrated in Spravato. There is no broad U.S. market of therapeutically interchangeable esketamine nasal-spray products, and generic ketamine injection is not an equivalent substitute for Spravato’s FDA-approved delivery system or labeled indications.
Spravato sales trajectory
| Fiscal year |
Reported global sales, approximate |
Year-over-year trend |
| 2021 |
$260 million |
Expansion from a small launch base |
| 2022 |
$518 million |
Approximately doubled |
| 2023 |
$689 million |
Approximately 33% growth |
| 2024 |
About $1.0 billion |
Approximately 45% growth |
Sources: Johnson & Johnson annual reports and earnings disclosures.[1]
The revenue curve has benefited from several factors:
- More patients are being referred after failing multiple conventional antidepressants.
- Psychiatric practices and specialty clinics have developed operating models for monitored nasal administration.
- Payers have become more familiar with the product’s utilization criteria.
- Patients and physicians increasingly recognize the speed of symptom improvement relative to conventional antidepressants.
- Treatment often continues after the induction phase, producing recurring maintenance revenue.
The principal limitations are the need for supervised administration, the cost of clinic infrastructure, prior authorization, variable reimbursement, and the requirement for repeated visits.
What are the main market drivers for esketamine hydrochloride?
Treatment-resistant depression
Treatment-resistant depression is the central commercial opportunity. Conventional antidepressants often require several weeks before efficacy can be evaluated. Esketamine can produce clinically meaningful effects more quickly in some patients, creating differentiation in a market where delayed response is a significant clinical problem.
High unmet need
Depression is prevalent, recurrent and associated with substantial health-care utilization. A significant subset of patients does not respond adequately to first-line treatment. The size of this population supports sustained demand even as oral antidepressants remain the dominant therapy class.
Administration-site expansion
Spravato is administered through certified sites that may include psychiatric offices, hospital outpatient departments and specialty behavioral-health clinics. Expansion of these sites increases geographic access and supports higher prescription volume.
Payer normalization
Coverage has improved as insurers have gained experience with utilization criteria. Reimbursement remains uneven, particularly for maintenance treatment and patients with incomplete documentation of prior antidepressant failures.
Label expansion
Additional approved use cases can increase the addressable population and reduce barriers to prescribing. The most commercially relevant regulatory development after the initial approval is the move toward broader use in treatment-resistant depression, including monotherapy where permitted by the updated label.
What is the competitive landscape for esketamine hydrochloride?
Spravato competes with both approved products and non-equivalent treatment alternatives.
| Competitor |
Product or therapy |
Competitive relationship |
| Generic ketamine |
Injectable racemic ketamine |
Lower-cost, off-label alternative; lacks Spravato’s branded nasal delivery and labeled indication |
| Conventional antidepressants |
SSRIs, SNRIs, atypical antidepressants |
First-line treatments and payer prerequisites |
| Brexanolone |
Zulresso |
Different indication and administration model |
| Zuranolone |
Zurzuvae |
Approved for postpartum depression, not a direct broad substitute for Spravato |
| Electroconvulsive therapy |
ECT |
Effective for severe or refractory depression but more invasive |
| Transcranial magnetic stimulation |
TMS |
Non-drug alternative with repeated treatment sessions |
| Compounded ketamine |
Oral, sublingual or nasal formulations |
Variable regulatory status, quality controls and evidence base |
| Psychedelic-assisted therapies |
Investigational or emerging treatments |
Longer-term competitive risk rather than an established substitute |
The closest practical competitor is off-label racemic ketamine. Ketamine clinics can offer lower prices and flexible dosing, but they generally lack Spravato’s FDA-approved indication, standardized device, branded clinical infrastructure and manufacturer-supported reimbursement pathway.
What patents protect esketamine hydrochloride and Spravato?
The esketamine molecule itself is not the main source of current U.S. exclusivity. Ketamine was discovered and commercialized decades ago, and the basic active ingredient does not provide a modern, long-duration composition-of-matter barrier.
Spravato’s protection is concentrated in:
- Intranasal formulations containing esketamine.
- Nasal delivery systems and dosing regimens.
- Methods of treating treatment-resistant depression.
- Methods involving repeated administration and clinical monitoring.
- Certain patient populations and treatment schedules.
Johnson & Johnson’s Janssen entities are the principal patent holders associated with Spravato. Publicly reported U.S. Orange Book records include formulation and method-of-use patents with expiration dates extending into the 2030s, subject to patent-term adjustment, patent-term extension, terminal disclaimers and litigation outcomes.[5]
Patent estate profile
| Patent category |
Protection value |
Generic vulnerability |
| Esketamine molecule |
Limited; underlying chemistry is old |
High |
| Intranasal formulation |
High if the ANDA product must use the same formulation |
Medium to high |
| Nasal-delivery device |
Potentially material |
Medium |
| Dosing regimen |
Relevant to labeling and inducement claims |
Medium |
| Treatment method |
Can delay labeled generic substitution |
Medium |
| Manufacturing process |
Important if difficult to replicate |
Medium |
| REMS and controlled distribution |
Regulatory barrier, not patent exclusivity |
Medium |
The strongest practical barriers are the combination of device/formulation claims, clinical-use patents, manufacturing controls and the operational requirements of the REMS program. These barriers do not prevent generic development, but they can increase development cost and delay market entry.
When does esketamine lose exclusivity?
There is no single exclusivity date for Spravato. Regulatory exclusivity, Orange Book patents, pediatric extensions and litigation outcomes operate separately.
The product’s U.S. new-chemical-entity exclusivity expired in 2024, five years after the February 2019 approval. That timing allows ANDA applicants to pursue approval subject to the listed patents and other regulatory requirements.[2]
Patent-based protection is expected to continue beyond the initial regulatory exclusivity period. Public patent records associated with Spravato indicate protection into the 2030s for certain formulations and methods.[5] The effective generic-entry date will depend on:
- Whether an ANDA applicant files a Paragraph IV certification.
- Whether Janssen files patent litigation within the statutory period.
- Whether the asserted patents survive litigation.
- Whether the generic applicant receives a favorable judgment or settlement.
- Whether the generic can design around device and formulation claims.
- Whether pediatric exclusivity or patent-term adjustments apply.
What is the Orange Book status of Spravato?
Spravato is listed in the FDA Orange Book as a prescription drug with patents covering its approved product and associated uses. The relevant patents are primarily formulation, delivery and method-of-use patents rather than a basic active-ingredient patent.[5]
The Orange Book does not guarantee that every listed patent will block a generic. An ANDA applicant may certify that a patent is invalid, unenforceable or will not be infringed. That Paragraph IV certification can trigger patent litigation.
The strategic significance of the Orange Book listing is therefore procedural. It creates a framework for patent challenges and can provide up to a 30-month stay of FDA approval if the innovator files timely litigation after receiving a Paragraph IV notice.[6]
Which companies are challenging esketamine patents?
As of the publicly reported information through 2024, no established U.S. commercial generic launch of an equivalent esketamine nasal spray had occurred, and no major successful Paragraph IV challenge had displaced Spravato.
Potential challengers include generic-drug companies with experience in:
- Complex nasal sprays.
- Controlled substances.
- Drug-device combination products.
- Psychiatric medicines.
- Paragraph IV litigation.
The principal challenge is technical rather than chemical. An applicant must demonstrate pharmaceutical equivalence and bioequivalence for a nasal product while addressing device performance, spray characteristics, dose delivery and manufacturing consistency.
A generic company could pursue one of several strategies:
- Copy the listed formulation and litigate the relevant patents.
- Design around formulation claims while preserving equivalent delivery.
- Seek approval for a different esketamine nasal formulation.
- Develop an injectable or other dosage form, although that would not be substitutable for Spravato.
- Challenge only selected method-of-use patents and accept a narrower label.
How strong is the patent estate for esketamine hydrochloride?
The patent estate is moderately strong commercially but weaker at the molecule level.
Strengths
- The product uses a specialized nasal delivery system.
- The treatment is administered under controlled clinical conditions.
- Method-of-use patents can complicate approval for the most commercially valuable indications.
- The product has established clinical demand and a large revenue base that supports patent enforcement.
- Manufacturing and device equivalence may be difficult to demonstrate.
Weaknesses
- Ketamine and esketamine have long prior-art histories.
- The active ingredient is not protected by a modern composition-of-matter patent.
- Method-of-use claims can be vulnerable to validity and non-infringement arguments.
- Physicians may use generic ketamine off-label.
- A generic with a narrow label could still compete for portions of the market.
- The REMS program is not itself a permanent market-exclusivity right.
Overall, Spravato has a stronger commercial barrier than a typical repurposed small molecule but a weaker fundamental patent position than a recently discovered chemical entity.
What patent litigation and settlement risks affect Spravato?
A Paragraph IV dispute would likely focus on three issues:
- Whether the generic product infringes intranasal formulation or device claims.
- Whether the method-of-use claims are valid and enforceable.
- Whether the generic label induces infringement of patented depression-treatment methods.
A settlement could provide a licensed entry date before the latest patent expiry. The value of such a settlement would depend on the expected litigation outcome, remaining sales, number of challengers and whether the agreement includes supply, licensing or restricted-use terms.
No major public settlement has established a definitive U.S. generic-entry date for Spravato through 2024. The absence of a launch does not eliminate future challenge risk. The product’s revenue growth increases the economic incentive for generic companies to challenge later-expiring patents.
What biosimilar risk exists for esketamine hydrochloride?
There is no biosimilar risk because esketamine hydrochloride is a small-molecule drug, not a biologic. The relevant pathway is an abbreviated new drug application, not a biosimilar application under the Public Health Service Act.
The commercial risk is therefore generic substitution, although nasal-device complexity may make the product more difficult to copy than a conventional tablet or capsule.
How does Spravato compare with generic ketamine?
| Factor |
Spravato |
Generic ketamine |
| Active ingredient |
Esketamine, S-enantiomer |
Usually racemic ketamine |
| FDA depression indication |
Yes |
Generally no |
| Delivery |
Standardized nasal spray |
Usually injection; compounded forms vary |
| Evidence package |
Controlled clinical development |
Often off-label evidence |
| Distribution |
Certified program and monitored administration |
Varies by setting |
| Cost |
High branded-product cost |
Usually lower drug cost |
| Payer coverage |
Increasing but restricted |
Variable and often limited |
| Substitutability |
Limited automatic substitution |
Not therapeutically interchangeable in the FDA sense |
| Patent risk |
Formulation, device and method patents |
Lower for the old active ingredient |
Generic ketamine places a ceiling on pricing and creates pressure on physicians and payers, but it does not automatically eliminate Spravato’s differentiation. Janssen benefits from the FDA label, standardized product, clinical evidence and established reimbursement processes.
What is the financial outlook for esketamine hydrochloride?
Spravato is transitioning from a launch product into a major neuroscience franchise. A reasonable commercial framework is:
| Scenario |
Revenue trajectory |
Main assumptions |
| Base case |
Continued growth through the late 2020s, followed by erosion |
Broader access, sustained maintenance use, no early generic launch |
| Upside case |
Growth materially above $1 billion |
Monotherapy adoption, improved reimbursement, international expansion, higher persistence |
| Downside case |
Flat or declining sales before the end of the decade |
Payer restrictions, clinic capacity limits, off-label ketamine competition, early generic entry |
Revenue quality is better than a short-course antidepressant because many patients receive repeated maintenance treatment. The product also has a large addressable population, but revenue depends on continued administration at certified sites. The number of treatment visits, not only new patient starts, is a key performance metric.
Margin pressure may arise from:
- Patient-support programs.
- Payer rebates.
- Clinic administration economics.
- Monitoring requirements.
- Expansion of field-based medical and commercial infrastructure.
- Manufacturing and device costs.
The strongest upside lever is broader use in treatment-resistant depression. The strongest downside lever is an approved generic nasal product that can meet the same clinical and reimbursement requirements.
What geographic markets support esketamine growth?
The United States remains the primary commercial market because it has the largest branded-reimbursement opportunity and the most developed specialty-clinic infrastructure.
Spravato received European authorization in 2019 for treatment-resistant major depression in adults who have not responded to at least two different antidepressant treatments during the current moderate-to-severe depressive episode.[7] European uptake is shaped by national health technology assessment, hospital budgets and country-specific reimbursement.
Other markets contribute less revenue but expand the long-term opportunity. International growth depends on local approval, controlled-substance rules, psychiatric capacity, reimbursement and the availability of certified administration sites.
What generic launch scenarios exist for Spravato?
Early challenge scenario
A generic applicant files a Paragraph IV certification, Janssen litigates, and the challenger obtains approval after a court decision or settlement. Entry could be limited initially to non-infringing indications or a restricted label.
Delayed-entry scenario
Janssen maintains the principal formulation and method patents through the early 2030s. Generic approval is delayed until patent expiry or a settlement date close to expiry.
Device-design-around scenario
A generic develops a different nasal device or formulation. The product may avoid some patents but face additional bioequivalence, manufacturing and regulatory work.
Off-label substitution scenario
Generic ketamine continues to take share without an approved equivalent nasal product. This would pressure utilization and pricing but would not create automatic pharmacy substitution.
Key Takeaways
- Esketamine hydrochloride is commercialized primarily as Spravato, Johnson & Johnson’s intranasal treatment for treatment-resistant depression.
- Global Spravato sales increased from about $518 million in 2022 to approximately $1 billion in 2024.
- The molecule has limited new patent protection because ketamine is an old active ingredient.
- The meaningful patent estate covers nasal formulations, delivery systems, dosing and treatment methods, with certain protection extending into the 2030s.
- U.S. new-chemical-entity exclusivity expired in 2024, but Orange Book patents remain relevant to generic entry.
- No biosimilar risk exists. Future competition will come from ANDA-based generics, off-label ketamine and alternative depression therapies.
- The main commercial constraints are supervised administration, payer authorization, clinic capacity and reimbursement.
- The main upside factors are monotherapy or label expansion, higher maintenance persistence and broader payer coverage.
- The principal revenue risk is an approved generic nasal product that can overcome device, formulation and method-of-use barriers.
FAQs
Is esketamine hydrochloride the same as ketamine hydrochloride?
No. Esketamine is the S-enantiomer of ketamine, while conventional ketamine hydrochloride is generally a racemic mixture containing both S- and R-enantiomers.
Is Spravato automatically substitutable with generic ketamine?
No. Generic ketamine injection and compounded ketamine products are not automatically substitutable for Spravato under U.S. pharmacy-substitution rules.
Does esketamine hydrochloride have composition-of-matter patent protection?
The active molecule does not have the type of current composition-of-matter protection associated with a newly discovered pharmaceutical. Spravato’s commercial protection is concentrated in formulation, delivery and method-of-use patents.
Can a generic company obtain approval for esketamine without copying Spravato’s device?
Potentially. A company could pursue a different device or formulation, but it would still need to satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, dose delivery and manufacturing quality.
Why is Spravato expensive compared with injectable ketamine?
Spravato pricing reflects branded-drug development, FDA-approved labeling, controlled distribution, clinical monitoring, device manufacturing and manufacturer-supported reimbursement infrastructure. Injectable generic ketamine has a much older and lower-cost supply base but is generally used off label for depression.
References
-
Johnson & Johnson. (2025). 2024 annual report and fourth-quarter earnings materials. Johnson & Johnson Investor Relations.
-
U.S. Food and Drug Administration. (2019, March 5). FDA approves new nasal spray medication for treatment-resistant depression; available only at certified doctor’s offices or clinics. https://www.fda.gov
-
U.S. Food and Drug Administration. (2020, July 31). FDA approves nasal spray medication for patients with major depressive disorder with acute suicidal ideation or behavior. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Spravato risk evaluation and mitigation strategy. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
-
European Medicines Agency. (2019). Spravato: EPAR - product information. https://www.ema.europa.eu
